Most people think of aging as something you see in a mirror. Researchers think of it differently. They measure aging through chemical marks on DNA, patterns that shift predictably as the body gets older and that can be read like a clock. When those clocks tick faster than expected, health risk tends to rise. When they tick slower, the biological picture looks younger than the calendar would suggest.
A research team published findings in Nature Communications from a 32-week, randomized, double-blind, placebo-controlled phase 2b trial that was originally designed to study visceral fat in adults living with HIV. As a post hoc exploratory analysis, the researchers added a second question: did a GLP-1 receptor agonist peptide affect how fast participants were aging at the epigenetic level? The answer, across multiple independent clocks, was yes.
What GLP-1 receptor agonists are
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone the gut releases after eating. It signals the pancreas to release insulin, tells the brain that food has arrived, and slows the rate at which the stomach empties. Synthetic peptides that mimic or extend the action of this hormone are called GLP-1 receptor agonists.
For years, researchers have primarily studied these peptides in the context of blood sugar regulation and body composition. More recently, scientists have begun asking a broader question: because chronic inflammation and metabolic dysfunction accelerate biological aging, could a peptide that reduces both also slow the aging process itself? The trial described here is among the first to test that hypothesis with actual clinical data.
The original trial and its cohort
The parent trial enrolled 84 adults, 45 assigned to the active peptide and 39 to placebo, all of whom were living with HIV and had a condition called lipohypertrophy, an abnormal redistribution of fat that can increase cardiovascular risk. The trial ran for 32 weeks. Its pre-specified primary endpoint was change in visceral adipose tissue, with secondary endpoints covering cardiometabolic markers and body composition.
Epigenetic aging was not part of the original plan. The research team conducted it as a post hoc exploratory analysis, which means it was added after the trial had begun and should be interpreted with appropriate caution. Blood samples collected at the start and at week 32 were profiled for DNA methylation patterns across hundreds of thousands of genomic sites.
Epigenetic clocks and what they measure
DNA methylation refers to chemical tags that attach to DNA without changing the underlying genetic code. These tags shift in consistent ways as people age, and statisticians have used large datasets to train mathematical models, called epigenetic clocks, that estimate biological age from those patterns. First-generation clocks were calibrated to chronological age. Second- and third-generation clocks were calibrated to health outcomes like mortality and disease, making them more relevant as measures of biological wear.
The research team used several of these clocks. PhenoAge and GrimAge V2 are well-validated second-generation measures. PCGrimAge and OMICmAge are newer, integrating additional molecular data. DunedinPACE is a third-generation clock designed to estimate the pace of aging rather than biological age at a single point. It produces a number representing how many biological years a person ages per calendar year, where 1.0 means aging in sync with chronological time.
What the data showed
In adjusted analyses, participants receiving the GLP-1 receptor agonist showed meaningful reductions across multiple clocks compared with those receiving placebo. PhenoAge showed a reduction of roughly 4.9 years per year of biological aging rate, with a p-value of 0.004. PCGrimAge showed a reduction of 3.1 units, GrimAge V2 showed 2.3, and OMICmAge showed 2.2, all with p-values below 0.01. RetroAge, another newer measure, showed a 2.2-unit reduction. DunedinPACE, the pace-of-aging clock, slowed by approximately 9 percent.
The researchers also applied what they call systems-based clocks, which are designed to estimate biological aging within specific organ systems or physiological domains. These clocks pointed toward parallel reductions in inflammation-related aging, brain aging measures, and heart aging measures among participants on the active peptide.
Taken together, the pattern across six distinct clocks is notable because each clock uses a different algorithm and draws on different methylation sites. When independent measures converge on a similar finding, researchers consider the signal more robust than if only one clock showed an effect.
Important limitations of the findings
The authors are explicit about the boundaries of what can be concluded. The epigenetic analysis was post hoc, meaning it was not pre-specified as a study endpoint. That design feature means the result is exploratory and hypothesis-generating rather than confirmatory. The sample was also modest, 84 participants total, and drawn from a specific population living with HIV, a condition associated with accelerated biological aging at baseline. Whether these findings would replicate in people without HIV remains an open question.
The follow-up period was 32 weeks, roughly eight months. Whether the observed changes in epigenetic clocks would persist, grow, or reverse over longer periods is unknown. The authors call for prospective trials designed from the outset to test whether GLP-1 receptor agonists can function as gerotherapeutics, a term meaning agents that target the biology of aging rather than specific diseases.
Why researchers consider this a meaningful signal
The literature on GLP-1 receptor agonists has grown rapidly, but most clinical evidence has focused on metabolic and cardiovascular endpoints measured in the conventional way, through blood tests, imaging, and clinical events. Epigenetic clocks offer a different angle: they attempt to capture the aggregate molecular state of the body rather than a single biomarker.
A recent abstract of this type, published in a peer-reviewed journal and based on randomized controlled data, provides a stronger foundation than observational studies or animal work. Randomization matters because it reduces the chance that healthier participants simply ended up in the treatment group by chance. The fact that effects appeared across multiple independent clocks, rather than just one, adds further weight.
Early data points at the possibility that targeting GLP-1 receptors influences pathways relevant to the biology of aging, not just the more familiar metabolic pathways. Inflammation is one plausible mechanism, since several of the clocks that showed the largest effects are sensitive to inflammatory signals in the blood. But researchers note that the mechanistic picture is not yet clear, and prospective studies designed to answer that question are the logical next step.
